PACIRA BIOSCIENCES, INC.

Drug pipeline (6)

Asset	Stage	Revenue	Trials	Status
EXPAREL	approved	$147.8MQ2 2026	18	approved
ZILRETTA	approved	$32.6MQ2 2026	8	approved
DEPOCYT	approved	—	5	approved
DEPODUR	approved	—	1	approved
TAFAMIDIS	phase3	—	36	completed, terminated

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (80)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT01509638	phase4	completed	2012-03-01	2012-10-01	Pacira Pharmaceuticals, Inc	A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501
NCT01509807	phase4	completed	2012-01-01	2012-10-01	Pacira Pharmaceuticals, Inc	A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504
NCT02058290	phase4	terminated	2011-12-01	2012-09-01	Pacira Pharmaceuticals, Inc	A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy
NCT01507220	phase4	terminated	2012-03-01	2012-07-01	Pacira Pharmaceuticals, Inc	A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301
NCT01507233	phase4	terminated	2012-05-01	2012-07-01	Pacira Pharmaceuticals, Inc	A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

FDA applications (4)

Application

Approved

Type

Applicant

Products

NDA 208845

2017-10-06

NDA

PACIRA PHARMACEUTICALS INC

NDA 022496

2011-10-28

NDA

PACIRA PHARMACEUTICALS INC

NDA 021671

2004-05-18

NDA

PACIRA PHARMACEUTICALS INC

NDA 021041

1999-04-01

NDA

PACIRA PHARMACEUTICALS INC